There are 11 papers on XPO1 in aging research: 1 observational study in people, 4 in animals, 5 in cells, 1 review.
1 new paper in 30 daysSee all 11 papers on XPO1
At a glance
The findings reach people, from one lab or study. 3 independent labs in 2 countries; 4 trials, 1 with no results posted.
“We found that some CH genotypes including JAK2, RUNX1, and XPO1 variants were associated with high hematologic malignancy risk.”
None of its findings points the other way.
- 3 independent labs in 2 countries
- 4 trials, 1 with no results posted
- Funders: CONACYT and others
- 1 of 4 findings with company ties
- 4 of 4 trials sponsored by developers of drugs aimed at it
- Humans1
- Animals3
- Model organisms1
- Cells5
Effects
2Nuclear TFEB levels
downin mice1
1 study
Nuclear TFEB levels
downin mice1
XPO1 decreases nuclear TFEB levels in mice (physiological aging).
“which resulted in a decrease of nuclear TFEB and STAT3”
Animalsphysiological aginghippocampus and cortex
Oxidative medicine and cellular longevity
HGPS cellular phenotype
upin human cells1
1 study
HGPS cellular phenotype
upin human cells1
XPO1 increases HGPS cellular phenotype in human cells (exogenous overexpression in normal fibroblasts).
“Exogenous overexpression of CRM1 on the other hand recapitulates the HGPS cellular phenotype in normal fibroblasts.”
Cellsexogenous overexpression in normal fibroblastsfibroblasts
Aging cell
Upstream
1Donor age
upin human cells1
1 study
Donor age
upin human cells1
donor age increases XPO1 in human cells (fibroblasts from healthy donors).
“CRM1 levels/activity increases with age in fibroblasts from healthy donors”
Cellsfibroblasts from healthy donorsfibroblasts
Aging cell
Associations
1Hematologic malignancy
upin humans1
1 study
Hematologic malignancy
upin humans1
XPO1 is linked with a higher risk of hematologic malignancy in humans (clonal hematopoiesis genotype in patients with nonhematologic cancer).
“We found that some CH genotypes including JAK2, RUNX1, and XPO1 variants were associated with high hematologic malignancy risk.”
Humansclonal hematopoiesis genotype in patients with nonhematologic cancern = 42,714
High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer
Blood advances